Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer - Concepedia

Concepedia

Publication | Open Access

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

DOI Full Paper Access

37

Citations

30

References

2020

Year

Florian Clatot, Anne Perdrix, Ludivine Beaussire, Justine Lequesne, Christelle Lévy, George Emile, Michaël Bubenheim, Sigrid Lacaille, Céline Calbrix, Laetitia Augusto,

Breast Cancer Research

References

	Year	Citations

Page 1